Checked.be
Active
BE 0727.381.719Private limited company
CASSIFARMA
Familie de Bayostraat 55 ·3000 Leuven, Belgium· 7 yrs active
Sector: Retail sale of pharmaceutical products
(47730)
Conclusion
CASSIFARMA has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €399k and a net result of €66k. Equity is growing by ~20.4% per year across the filed fiscal years. Its solvency ranks better than 73% of 480 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €399k |
| Net result | €66k |
| Better than sector | 73% |
| Active | 7 yrs |
Financial profile
76
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
64
Profitability
83
Solvency
54
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2019, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
64
/ 100
Healthy
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€25k
estimate, not credit advice
Score history
43
2022
61
2023
56
2024
64
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 0.55 (< 1.0)
-10
Quick ratio
Quick ratio 0.55 (< 0.6)
-5
Leverage
Debt/equity 1.36 (< 2.0)
+3
Profitability
ROE 17% (≥ 10%)
+10
Interest coverage
Interest coverage 7.4× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 28-07-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~20.4%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 47, Retail trade · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 42.3% | 21.2% | |
| Net result | €66k | €32k | |
| Equity | €399k | €163k | |
| Gross operating margin | €115k | €281k | |
| Employees (FTE) | 0.0 | 4.9 |
€114k
+12.1%
22-25
€66k
+13.8%
22-25
€67k
+13.7%
22-25
€943k
-0.3%
22-25
€399k
+19.6%
22-25
€-66k
+19.9%
22-25
0
-
22-25
€0
-100.0%
22-25
€31k
+19.3%
22-25
€833
-3.0%
22-25
€544k
-11.2%
22-25
€147k
-11.3%
22-25
€395k
-11.2%
22-25
0.55
+9.7%
22-25
0.55
+9.7%
22-25
42.3%
+20.0%
22-25
1.36
-25.7%
22-25
16.6%
-4.9%
22-25
7.0%
+14.1%
22-25
7.43
+18.6%
22-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | micro schema | micro schema |
| Revenue | - | - | - | - |
| EBITDA | €114k | €101k | €117k | €98k |
| Net profit | €66k | €58k | €67k | €54k |
| Cash flow | €67k | €59k | €72k | €58k |
| Staff costs | - | - | €0 | €2k |
| Income taxes | €31k | €26k | €32k | €27k |
| Dividends | €833 | €859 | €833 | €800 |
| Total assets | €943k | €946k | €936k | €923k |
| Equity | €399k | €333k | €276k | €210k |
| Debt | €544k | €612k | €660k | €713k |
| of which ≤ 1y | €147k | €165k | €157k | €166k |
| of which > 1y | €395k | €445k | €494k | €545k |
| Working capital | €-66k | €-82k | €-86k | €-110k |
| Employees (FTE) | 0.0 | 0.0 | - | - |
Note: these years are not on the same basis. The filed schemas differ (abbreviated schema, micro schema), so the columns are not directly comparable.
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 0.55 | 0.50 | 0.45 | 0.34 |
| Quick ratio | 0.55 | 0.50 | 0.45 | 0.34 |
| Working capital ratio | -7.0% | -8.7% | -9.2% | -11.9% |
| Solvency | 42.3% | 35.2% | 29.5% | 22.8% |
| Debt / equity | 1.36 | 1.84 | 2.39 | 3.39 |
| Long-term debt ratio | 0.99 | 1.34 | 1.79 | 2.59 |
| Interest coverage | 7.43 | 6.26 | 9.04 | 7.82 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 7.0% | 6.2% | 7.1% | 5.8% |
| ROE | 16.6% | 17.5% | 24.1% | 25.6% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (24 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €943k | €946k | €936k | €923k |
| Fixed assets | 21/28 | €862k | €863k | €865k | €867k |
| Tangible fixed assets | 22/27 | €1k | €2k | €4k | €6k |
| Financial fixed assets | 28 | €861k | €861k | €861k | €861k |
| Current assets | 29/58 | €81k | €83k | €71k | €56k |
| Amounts receivable within one year | 40/41 | €73k | €59k | €44k | €13k |
| Cash & bank | 54/58 | €7k | €23k | €21k | €43k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €943k | €946k | €936k | €923k |
| Equity | 10/15 | €399k | €333k | €276k | €210k |
| Contributions / capital | 10/11 | €40k | €40k | €40k | €40k |
| Reserves | 13 | €359k | €293k | €236k | €170k |
| Accumulated profits (losses) | 14 | €0 | €0 | €0 | - |
| Amounts payable | 17/49 | €544k | €612k | €660k | €713k |
| Amounts payable after one year | 17 | €395k | €445k | €494k | €545k |
| Amounts payable within one year | 42/48 | €147k | €165k | €157k | €166k |
| Trade debts payable within one year | 44 | €713 | €23k | €788 | €951 |
| Income statement | |||||
| Gross operating margin | 9900 | €115k | €102k | €118k | €101k |
| Operating result | 9901 | €113k | €101k | €112k | €93k |
| Financial income | 75 | €0 | €0 | €16 | €1 |
| Financial charges | 65 | €15k | €16k | €13k | €13k |
| Result before taxes | 9903 | €98k | €85k | €99k | €81k |
| Income taxes | 67/77 | €31k | €26k | €32k | €27k |
| Net result for the period | 9904 | €66k | €58k | €67k | €54k |
| Result to be appropriated | 9905 | €66k | €58k | €67k | €54k |
Legal Structure
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 22-05-2019 |
| Status | Active |
| Postal code | 3000 |
Establishment units
CASSIFARMA
since 20192.289.304.423
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24502C0496/00K006 | Flanders | 168 m² | 1 · 59 m² | 11.4 m · 3 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
28-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
14-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 31 days late
2023
31-12
Financial
Highest result since 2022net €67k ▲23.7%
Net result €67k, the highest in the series.
21-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 21 days late
2022
09-09
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 40 days late
2021
30-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
10-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Retail sale of pharmaceutical products47730
Names & trade names
| Legal nameNL | CASSIFARMA |
Similar companies
APOTHEEK MAST
BE 0465.145.979 · Merchtem
MEDITHERA
BE 0429.134.433 · Rixensart
APOTHEEK DE BAERE
BE 0877.841.783 · Liedekerke
Pharmacie de la Chasse Royale
BE 0867.368.654 · Frameries
PHARMACIE DUBUISSON
BE 0508.493.004 · Welkenraedt